Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
March 25 2022 - 7:30AM
Business Wire
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the
“Company”) today announced that, as previously disclosed in its
Annual Report on Form 10-K for the year ended December 31, 2021,
which was filed on March 24, 2022 with the Securities and Exchange
Commission, the audited financial statements contained an
unqualified audit opinion from its independent registered public
accounting firm that included an explanatory paragraph related to
the Company’s ability to continue as a going concern. See further
discussion in footnote 1 to the Company’s financial statements
included in the Company’s Annual Report on Form 10-K. This
announcement is made pursuant to NYSE American LLC Company Guide
Section 610(b), which requires public announcement of the receipt
of an audit opinion containing a going concern paragraph. This
announcement does not represent any change or amendment to the
Company’s financial statements or to its Annual Report on Form 10-K
for the year ended December 31, 2021.
About Oragenics, Inc.
Oragenics, Inc. is a development-stage company dedicated to
fighting infectious diseases including coronaviruses and
multidrug-resistant organisms. Its lead product is NT-CoV2-1, an
intranasal vaccine candidate to prevent COVID-19 and variants of
the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus
spike protein research licensed from the NIH and the NRC with a
focus on reducing viral transmission and offering a more
patient-friendly intranasal administration. Its lantibiotics
program features a novel class of antibiotics against bacteria that
have developed resistance to commercial antibiotics. For more
information about Oragenics, please visit www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on management’s beliefs and assumptions and
information currently available. The words "believe," "expect,"
"anticipate," "intend," "estimate," "project" and similar
expressions that do not relate solely to historical matters
identify forward-looking statements. Investors should be cautious
in relying on forward-looking statements because they are subject
to a variety of risks, uncertainties, and other factors that could
cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are
not limited to those described in our Form 10-K and other filings
with the U.S. Securities and Exchange Commission. All information
set forth in this press release is as of the date hereof. You
should consider these factors in evaluating the forward-looking
statements included in this press release and not place undue
reliance on such statements. We do not assume any obligation to
publicly provide revisions or updates to any forward-looking
statements, whether as a result of new information, future
developments or otherwise, should circumstances change, except as
otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220325005111/en/
Oragenics Corporate Contact: Michael Sullivan,
813-286-7900 Chief Financial Officer msullivan@oragenics.com
or
LHA Investor Relations Tirth T. Patel 212-201-6614
tpatel@lhai.com
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024